# A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

> **NCT07197554** · PHASE1 · RECRUITING · sponsor: **SEED Therapeutics, Inc.** · enrollment: 171 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Ewing Sarcoma
- Hepatocellular Carcinoma (HCC)
- Biliary Tract Cancer (BTC)

## Interventions

- **DRUG:** ST-01156

## Key facts

- **NCT ID:** NCT07197554
- **Lead sponsor:** SEED Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-01
- **Primary completion:** 2029-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 171 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07197554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07197554, "A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT07197554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*